The 3q29 Deletion and 3q29 Duplication: Architecture of Behavioral Phenotypes

The 3q29 deletion syndrome is caused by a deletion of a small part of human chromosome 3, and the duplication syndrome is caused by a duplication of this same small region. The purpose of this study is to understand the medical and behavioral consequences of these syndromes.

Study Overview

• Status: Recruiting
• Conditions: Microdeletion 3q29 Syndrome; Microduplication 3q29 Syndrome

Detailed Description

People with 3q29 deletion syndrome are missing a small part of a region on human chromosome 3, and people with 3q29 duplication syndrome have an extra part of their chromosome 3. Sometimes babies are born with a deletion or duplication of part of human chromosome 3, even though their parents have an intact chromosome 3. This is called de novo (or new) abnormalities.

• Study Type: Observational
• Enrollment (Estimated): 800

Contacts and Locations

• Study Contact: Name: Jennifer G Mulle, MHS, PhD; Phone Number: (848) 445-9866; Email: jennifer.mulle@rutgers.edu
• Study Contact Backup: Name: Teresa Irving; Email: tmi21@cabm.rutgers.edu

Study Locations

• United States
  • New Jersey
    • Piscataway, New Jersey, United States, 08854
      • Recruiting
      • Internet-Based
      • Contact: Teresa Irving, MSW; Email: tmi21@cabm.rutgers.edu
      • Contact: Jennifer Mulle, MHS, PhD; Phone Number: (848) 445-9866; Email: jennifer.mulle@rutgers.edu

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Child; Adult; Older Adult
• Accepts Healthy Volunteers: Yes

• Sampling Method: Probability Sample

Study Population

Study subjects will be recruited by an internet-based registry. The registry website will be indexed on popular search enginesand potential study subjects can elect to visit the website as they choose. Study population will be individuals with the 3q29 deletion or 3q29 duplication and their family members, although in most cases the primary caregiver of the 3q29 deletion or duplication individual will contribute the data. This study aims to collect data on approximately 200 individuals with the 3q29 deletion and 100 individuals with the 3q29 duplication. For comparison purposes, the study will assess an equal number of matched number of unaffected siblings and control individuals without the 3q29 deletion or duplication.

Description

Inclusion Criteria:

• Diagnosis of 3q29 deletion or 3q29 duplication
• Consent from parents or guardians or an adult with 3q29 deletion or 3q29 duplication that does not require a legal guardian or an adult who is the healthy sibling of an individual with 3q29 deletion or 3q29 duplication or a healthy age-matched control

Exclusion Criteria:

• Clinically significant medical disease that would prohibit participation in the study procedures

Study Plan

How is the study designed?

Design Details

• Observational Models: Case-Control
• Time Perspectives: Prospective

Number of groups / cohorts

4

Cohorts and Interventions

Group / Cohort
Healthy Controls; Unrelated age-matched controls without 3q29 deletion or duplication
3q29 deletion; Individuals with 3q29 deletion syndrome (sometimes called "3q29 micro deletion")
3q29 duplication; Individuals with 3q29 duplication syndrome (sometimes called "3q29 micro duplication")
Parents; parents of individuals with the 3q29 deletion or 3q29 duplication

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Range of medical conditions associated with the 3q29 deletion and duplication, assessed by the percent of patients reporting specific conditions present	A medical questionnaire designed to collect data on commonly reported medical conditions associated with the 3q29 deletion or duplication will be administered.	5 years

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Feeding questionnaire	Feeding questionnaire is an 11-item questionnaire to document the specific feeding problems experienced by individuals with 3q29 deletion syndrome.	Baseline
Score on the Social Responsiveness Scale (SRS)	The SRS is a 65-item, caregiver-rated assessment scale that measures observable items on social behavior and social language use, as well as characteristics of autism in a naturalistic social setting. Each item is rated on a scale from 0 (never true) to 3 (almost always true). The SRS total raw score ranges from 0 to 195; a higher score indicates greater severity of social impairment.	Baseline, 5 years
Score on the Social Communication Questionnaire (SCQ)	The SCQ is a 40-item, parent-reported screening measure that taps the symptomatology associated with autism spectrum disorder (ASD). The items are in a yes/no format and are translated to scores of 1 (yes) or 0 (no). The threshold reflecting the need for diagnostic assessment is a score of 15. Higher scores are indicative of autism characteristics.	Baseline, 5 years
Score on the Child Behavior Checklist (CBCL)	The CBCL is a 120-item, parent-reported checklist that includes several competence items, open-ended items for describing the child's illnesses, disabilities, concerns about the child, best things about the child, and several items to rate behavioral, emotional, and social problems. Responses are recorded on a Likert scale: 0 = Not True, 1 = Somewhat or Sometimes True, 2 = Very True or Often True. The standardized score is computed by determining the z-score by subtracting the mean for the subject's age group and gender from the raw score and then dividing this by the standard deviation for the subject's age group and gender. Next, multiply the z-score by 15 and then add 100. For activities scale, social scale, school scale, and total competence scale, higher values indicate higher competencies. For Internalizing problems, externalizing problems, and total problems, higher values indicate more problems.	Baseline, 5 years
Prodromal Questionnaire - Brief Version (PQ-B)	The PQ-B is a 21-item self-report screening measure for psychosis risk syndromes. Each item is rated on a five-point Likert scale from 1 (strongly disagree) to 5 (strongly agree). The total score ranges from 0 to 21, where respondents receive 1 point for each "yes" response. The threshold reflecting the need for diagnostic assessment is a score of 3 or higher.	Baseline, 5 years
Performance on the Penn Computerized Neurobahavioral Test battery (PennCNB)	The PennCNB is a computerized assessment of domains of cognitive ability. It is scored on a z-score scale, where the mean is 0, positive scores indicate scores above the mean (better performance) and negative scores are below the mean (worse performance). Most acres wil fall between -3 and 3.	Baseline, 5 years
Structured Interview for Psychosis Risk Syndromes (SIPS)	The Structured Interview for Psychosis Risk Syndromes (SIPS) is a semi-structured interview designed to assess early signs of psychosis. For each scale scores range from 0-6, with higher scores indicating worse performance	Baseline
Score on the Vineland	The Vineland is a questionnaire designed to assess adaptive behavior. It is scores on a standard scale, where scores range from 0-160 with arena of 100. Higher scores indicated petter performance.	5 years
T-score on the Behavior Rating Inventory of Executive Function (BRIEF)	The BRIEF is a questionnaire designed to assess executive functioning. It is scored on a T-score scale, where higher scores indicate more disability in this domain. Scores range from 0-100, higher scores indicate worse executive function.	Baseline, 5 years

Collaborators and Investigators

• Sponsor: Rutgers, The State University of New Jersey
• Investigators: Principal Investigator: Jennifer Mulle, MHS, PhD, Rutgers University

Study record dates

Study Major Dates

• Study Start (Actual): July 1, 2013
• Primary Completion (Estimated): January 1, 2028
• Study Completion (Estimated): January 1, 2028

Study Registration Dates

• First Submitted: May 15, 2015
• First Submitted That Met QC Criteria: May 15, 2015
• First Posted (Estimated): May 19, 2015

Study Record Updates

• Last Update Posted (Actual): May 20, 2026
• Last Update Submitted That Met QC Criteria: May 18, 2026
• Last Verified: May 1, 2026

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Pathologic Processes; Disease; Chromosome 3q29 Deletion Syndrome; Chromosome 3q29 Duplication Syndrome
• Other Study ID Numbers: Pro2021001976

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No